{"filing":{"accession_number":"0001193125-26-275976","cik":"0001833214","ticker":"SABSW","company_name":"SAB Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"sabs-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526275976/sabs-20260618.htm"},"events":[{"id":11920,"run_id":10491,"accession_number":"0001193125-26-275976","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from SAB Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing reports the outcomes of two proposals: (1) election of four Class II directors (David Zaccardelli, David Link, Katie Ellias, and Andrew Moin) with detailed vote tallies, and (2) ratification of EisnerAmper LLP as independent auditor. The disclosure includes quorum information (76.12% attendance) and complete voting results for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","company_name":"SAB Biotherapeutics, Inc.","ticker":"SABSW","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8635,"accession_number":"0001193125-26-275976","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from SAB Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing reports the outcomes of two proposals: (1) election of four Class II directors (David Zaccardelli, David Link, Katie Ellias, and Andrew Moin) with detailed vote tallies, and (2) ratification of EisnerAmper LLP as independent auditor. The disclosure includes quorum information (76.12% attendance) and complete voting results for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:37:07.926110+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8635,"accession_number":"0001193125-26-275976","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from SAB Biotherapeutics' 2026 Annual Meeting of Stockholders held on June 18, 2026. The filing reports the outcomes of two proposals: (1) election of four Class II directors (David Zaccardelli, David Link, Katie Ellias, and Andrew Moin) with detailed vote tallies, and (2) ratification of EisnerAmper LLP as independent auditor. The disclosure includes quorum information (76.12% attendance) and complete voting results for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:37:07.926110+00:00","company_name":"SAB Biotherapeutics, Inc.","ticker":"SABSW","filing_date":"2026-06-18"}]}